You are here: Industry Insights > lymphoma

News List

FDA approves Kyowa Kirin’s Poteligeo to treat two lymphoma types pharmaceutical-technology
August 13, 2018
The US Food and Drug Administration (FDA) has granted approval to biotechnology company Kyowa Kirin’s Poteligeo (mogamulizumab-kpkc) injection to treat adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).
H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma biospace
April 18, 2018
H3 Biomedicine Inc today announced novel findings from a comprehensive genomic analysis of 6,235 patients across 15 hematologic malignancies.
Commitment to Curing Cancer: High School Fundraising Campaign Raises $192,000+ in Seven Weeks For Th biospace
March 05, 2018
The Leukemia & Lymphoma Society's(LLS) second annual Students of the Year campaign exceeded all expectations, with 21 Candidate Teams, comprised of 36 extraordinary high school students, raising over $192,000 to help find cancer cures.
Mid-infrared spectroscopy used to diagnose lymphoma and melanoma europeanpharmaceuticalreview
December 14, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer…
Leukemia & Lymphoma Society Funds $46 Million in New Research americanpharmaceuticacreview
November 22, 2017
The Leukemia & Lymphoma Society has committed an additional $46 million to fund the science at medical institutions around the world. LLS has invested more than $1 billion in cancer research in its nearly 70-year history.
Mundipharma launches new treatment for lymphoma biospectrumasia
August 31, 2017
In 2016, Mundipharma filed the approval application for the medicine based on the results both from the Japan study and a global study, which led to marketing authorization, approval and now the launch.
Novartis’ lymphoma treatment receives FDA breakthrough therapy designation europeanpharmaceuticalreview
April 20, 2017
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’ CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy...
Phase II Lymphoma study of Daratumumab will not continue to stage 2 europeanpharmaceuticalreview
April 05, 2017
Genmab and Janssen Biotech have decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL).

Previous page 1 2 3 4 5 Next page